Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Sep 19;2(9):e875.
doi: 10.1371/journal.pone.0000875.

Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings

Affiliations

Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings

Ume L Abbas et al. PLoS One. .

Abstract

Background: The potential impact of pre-exposure chemoprophylaxis (PrEP) on heterosexual transmission of HIV-1 infection in resource-limited settings is uncertain.

Methodology/principle findings: A deterministic mathematical model was used to simulate the effects of antiretroviral PrEP on an HIV-1 epidemic in sub-Saharan Africa under different scenarios (optimistic, neutral and pessimistic) both with and without sexual disinhibition. Sensitivity analyses were used to evaluate the effect of uncertainty in input parameters on model output and included calculation of partial rank correlations and standardized rank regressions. In the scenario without sexual disinhibition after PrEP initiation, key parameters influencing infections prevented were effectiveness of PrEP (partial rank correlation coefficient (PRCC) = 0.94), PrEP discontinuation rate (PRCC = -0.94), level of coverage (PRCC = 0.92), and time to achieve target coverage (PRCC = -0.82). In the scenario with sexual disinhibition, PrEP effectiveness and the extent of sexual disinhibition had the greatest impact on prevention. An optimistic scenario of PrEP with 90% effectiveness and 75% coverage of the general population predicted a 74% decline in cumulative HIV-1 infections after 10 years, and a 28.8% decline with PrEP targeted to the highest risk groups (16% of the population). Even with a 100% increase in at-risk behavior from sexual disinhibition, a beneficial effect (23.4%-62.7% decrease in infections) was seen with 90% effective PrEP across a broad range of coverage (25%-75%). Similar disinhibition led to a rise in infections with lower effectiveness of PrEP (< or = 50%).

Conclusions/significance: Mathematical modeling supports the potential public health benefit of PrEP. Approximately 2.7 to 3.2 million new HIV-1 infections could be averted in southern sub-Saharan Africa over 10 years by targeting PrEP (having 90% effectiveness) to those at highest behavioral risk and by preventing sexual disinhibition. This benefit could be lost, however, by sexual disinhibition and by high PrEP discontinuation, especially with lower PrEP effectiveness (< or = 50%).

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Simplified Flow Diagram of Model with PrEP Implementation.
Figure 2
Figure 2. Trends in HIV-1 Prevalence among Urban Antenatal Clinic Attendees in Zambia from 1994 to 2004 and the Simulated Adult Female Population.
Figure 3
Figure 3. Contour Graph for Decline in Cumulative Infections (%) as a Function of Effectiveness of PrEP and Increase in Risk Behavior Assuming Optimistic Scenario.
Negative numbers reflect increase in infections.

References

    1. Garcia-Lerma J, Otten R, Qari S, Jackson E, Luo W, et al. Denver, CO: 2006. Prevention of rectal SHIV transmission in macaques by tenofovir/FTC combination [Abstract 32LB]. 13th Conference on Retroviruses and Opportunistic Infections.
    1. Subbarao S, Otten RA, Ramos A, Kim C, Jackson E, et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis. 2006;194:904–911. - PubMed
    1. Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science. 1995;270:1197–1199. - PubMed
    1. Van Rompay KK, McChesney MB, Aguirre NL, Schmidt KA, Bischofberger N, et al. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis. 2001;184:429–438. - PubMed
    1. Van Rompay KK, Miller MD, Marthas ML, Margot NA, Dailey PJ, et al. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J Virol. 2000;74:1767–1774. - PMC - PubMed

Publication types

Substances